Good morning Chairman Headland and members of the Committee. My name is Neil Charvat, and I am the Director of the Tobacco Prevention and Control Program for the North Dakota Department of Health. I am here to provide testimony in support of Senate Bill 2355.

Tobacco prevention and control efforts in North Dakota focus on guidance provided by the Centers for Disease Prevention and Control (CDC) Best Practices for Comprehensive Tobacco Control Programs (Best Practices). Best Practices provides evidence-based interventions to prevent tobacco product use initiation, increase quitting tobacco use, and reduce exposure to secondhand smoke. Senate Bill 2355 provides the opportunity to study the designation of electronic smoking devices, or electronic nicotine delivery systems (ENDS), as a tobacco product. This designation would positively impact the ability to monitor ENDS data and specifically provide information on ENDS product initiation and usage patterns.

Nearly one in five high school students uses tobacco products. Additionally, adolescent use of ENDS (e-cigarettes/vaping devices) has significantly increased from 1.6 percent in 2011 to 19.1 percent in 2017 (ND Youth Risk Behavior Survey). JUUL, an ENDS device resembling a computer USB storage device, has taken over almost three-quarters of the ENDS market in just a few years. JUUL has caused widespread concern because of its popularity with youth. On September 12, 2018, the Food and Drug Administration (FDA) declared that youth use of ENDS has reached “nothing short of an epidemic proportion of growth.”

Citing statistics regarding youth use of ENDS is difficult, since these devices are not classified as “tobacco products.” SB 2355 would provide the opportunity to study the change of this classification from general merchandise to tobacco products. If this change occurred, it would require that retailers have a tobacco license to sell these products. Additional benefits would include:

- Helping retailers to justify checking identification for proof of age as they already do with other tobacco products.
• Assisting groups statewide with performing tobacco compliance checks in retailer establishments to include youth purchase attempts of ENDS with other tobacco products, such as cigarettes. With ENDS lacking this state-level designation, many compliance statutes are not possible for ENDS.

• Allowing closer monitoring of the amount of ENDS sales; thereby, assisting efforts to gather data regarding usage of these products.

Beyond youth initiation, there are concerns about the promotion of ENDS to adults as cessation (quitting) devices for cigarette smokers. The Tobacco Prevention and Control Program views ENDS as tobacco products, so using these products as a replacement for cigarettes is not quitting tobacco, but merely a substitution. There are health care advocates that embrace ENDS as a harm reduction product to help curb the thousands of deaths directly caused by cigarette use. They are so focused on this point, they are overlooking the bigger picture: ENDS are not proven to be a safe and effective tool for quitting smoking. The ENDS industry is making efforts to confuse the definition of “tobacco” products and “nicotine” products. According to the JUUL Labs website: “Nicotine is a stimulant that comes from the tobacco plant. We use highly purified/USP grade/pharmaceutical grade nicotine” and “No tobacco-based nicotine e-liquid product should be considered safe.” There should be no confusion about the source of nicotine for these products.

The current FDA approved nicotine replacement therapy (NRT) products are designed to help people addicted to nicotine quit their addiction by gradually stepping down strength levels of nicotine. The difference between ENDS and NRT is that the NRT products have gone through rigorous FDA testing to prove safety and efficacy. Despite being in existence for over 10 years, no ENDS devices have been approved by the FDA as a cessation medication.

The FDA is investigating the possibility of approving other tobacco products as “modified risk” products, defined as something that can be used instead of cigarettes because they may cause less death and disease than cigarettes do. The tobacco industry, the ENDS industry, many health organizations and countries (such as the United Kingdom) have embraced this concept. Studies provided to support these efforts lack the current level of scientific
proof to conclusively demonstrate the safety of these products. Vague
studies and anecdotal evidence do not warrant embracing ENDS to save
lives.

Switching from cigarettes to ENDS is merely changing the delivery method
for nicotine addiction. New studies show that this is an actual trend. Our
own tobacco cessation service, NDQuits, has a lower success rate for people
to quit smoking who continue to use ENDS (33.2 percent vs. 22.5 percent
30-day abstinence rate at 7-month follow-up). The FDA has discussed plans
to identify modified-risk versus full-risk tobacco products. However, plans
and studies that use the words “may be safer,” “may be less dangerous” and
other similar statements do not correlate to success in saving lives. The FDA
has effectively deferred comprehensive regulation of ENDS products until
2022.

In the short time that ENDS have been in existence, we have seen increased
nicotine addiction in youth, poisonings among youth and adults, and
exploding devices. A new study released by the University of California, San
Francisco relates ENDS use to increased risks of myocardial infarctions (heart
attacks). It took medical science 40 years to identify the negative impact of
cigarette smoking on populations. Without clear data to prove the safety of
ENDS, it would be premature to promote these devices as a safe alternative
to nicotine use.

For these reasons, we ask you to support passage of SB 2355. This
concludes my testimony. I am happy to answer any questions you may have.